Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.

Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Bruckner HW, Hall FL.

Int J Oncol. 2006 Nov;29(5):1053-64.

PMID:
17016635
2.

Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.

Gordon EM, Chan MT, Geraldino N, Lopez FF, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL.

Int J Oncol. 2007 Jun;30(6):1297-307.

PMID:
17487349
3.

First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.

Gordon EM, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL.

Int J Oncol. 2004 Jan;24(1):177-85.

PMID:
14654955
4.

Rexin-G, a targeted genetic medicine for cancer.

Gordon EM, Hall FL.

Expert Opin Biol Ther. 2010 May;10(5):819-32. doi: 10.1517/14712598.2010.481666. Review.

PMID:
20384524
5.

Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.

Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB, Hall FL.

Int J Oncol. 2008 Oct;33(4):665-75.

PMID:
18813779
7.

The 'timely' development of Rexin-G: first targeted injectable gene vector (review).

Gordon EM, Hall FL.

Int J Oncol. 2009 Aug;35(2):229-38. Review.

PMID:
19578735
8.

Technology evaluation: Rexin-G, Epeius Biotechnologies.

Morse M.

Curr Opin Mol Ther. 2005 Apr;7(2):164-9. Review.

PMID:
15844625
9.

Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.

Hall FL, Levy JP, Reed RA, Petchpud WN, Chua VS, Chawla SP, Gordon EM.

Oncol Rep. 2010 Oct;24(4):829-33.

PMID:
20811660
10.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
11.

Cancer gene therapy steadily advances.

Brower V.

J Natl Cancer Inst. 2008 Sep 17;100(18):1276-8. doi: 10.1093/jnci/djn335. Epub 2008 Sep 9. No abstract available.

PMID:
18780858
12.

Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.

Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW, Hall FL.

Cancer Res. 2000 Jul 1;60(13):3343-7.

13.

Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.

Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J.

Mol Ther. 2008 May;16(5):979-84. doi: 10.1038/mt.2008.29. Epub 2008 Mar 18.

14.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
15.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
16.

Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.

Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM.

Mol Ther. 2009 Sep;17(9):1651-7. doi: 10.1038/mt.2009.126. Epub 2009 Jun 16.

17.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
18.

Nanotechnology blooms, at last (Review).

Gordon EM, Hall FL.

Oncol Rep. 2005 Jun;13(6):1003-7. Review.

PMID:
15870914
19.

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM, Hall FL.

Mol Ther. 2010 Feb;18(2):435-41. doi: 10.1038/mt.2009.228. Epub 2009 Oct 13.

20.

Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.

Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, Ozawa K.

J Gene Med. 2009 May;11(5):373-81. doi: 10.1002/jgm.1313.

PMID:
19274675

Supplemental Content

Support Center